Supernus Pharmaceuticals, Inc. (SUPN)
USD 35.46
(-2.1%)
USD 35.46
(-2.1%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 607.52 Million USD | -8.95% |
| 2022 | 667.23 Million USD | 15.09% |
| 2021 | 579.77 Million USD | 11.41% |
| 2020 | 520.39 Million USD | 32.5% |
| 2019 | 392.75 Million USD | -3.95% |
| 2018 | 408.89 Million USD | 35.29% |
| 2017 | 302.23 Million USD | 40.57% |
| 2016 | 215 Million USD | 48.87% |
| 2015 | 144.42 Million USD | 18.34% |
| 2014 | 122.04 Million USD | 915.43% |
| 2013 | 12.01 Million USD | 712.09% |
| 2012 | 1.48 Million USD | 84.31% |
| 2011 | 803 Thousand USD | 657.55% |
| 2010 | 106 Thousand USD | -99.72% |
| 2009 | 37.92 Million USD | 326.65% |
| 2008 | 8.88 Million USD | 109.97% |
| 2007 | 4.23 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 168.32 Million USD | 17.18% |
| 2024 Q3 | 175.68 Million USD | 4.37% |
| 2024 Q1 | 143.64 Million USD | -12.58% |
| 2023 Q2 | 135.56 Million USD | -11.84% |
| 2023 Q1 | 153.76 Million USD | -8.11% |
| 2023 FY | 607.52 Million USD | -8.95% |
| 2023 Q4 | 164.31 Million USD | 6.78% |
| 2023 Q3 | 153.88 Million USD | 13.51% |
| 2022 Q4 | 167.32 Million USD | -5.65% |
| 2022 FY | 667.23 Million USD | 15.09% |
| 2022 Q3 | 177.35 Million USD | 4.29% |
| 2022 Q1 | 152.5 Million USD | -4.11% |
| 2022 Q2 | 170.05 Million USD | 11.5% |
| 2021 Q2 | 141.32 Million USD | 7.94% |
| 2021 FY | 579.77 Million USD | 11.41% |
| 2021 Q4 | 159.05 Million USD | 7.13% |
| 2021 Q1 | 130.93 Million USD | -8.79% |
| 2021 Q3 | 148.46 Million USD | 5.05% |
| 2020 Q3 | 155.13 Million USD | 22.41% |
| 2020 FY | 520.39 Million USD | 32.5% |
| 2020 Q1 | 94.97 Million USD | -5.45% |
| 2020 Q2 | 126.72 Million USD | 33.43% |
| 2020 Q4 | 143.55 Million USD | -7.46% |
| 2019 Q2 | 104.69 Million USD | 22.49% |
| 2019 FY | 392.75 Million USD | -3.95% |
| 2019 Q1 | 85.47 Million USD | -26.27% |
| 2019 Q4 | 100.44 Million USD | -1.66% |
| 2019 Q3 | 102.14 Million USD | -2.44% |
| 2018 Q3 | 102.99 Million USD | 3.47% |
| 2018 Q2 | 99.53 Million USD | 10.07% |
| 2018 Q1 | 90.42 Million USD | 2.25% |
| 2018 Q4 | 115.93 Million USD | 12.56% |
| 2018 FY | 408.89 Million USD | 35.29% |
| 2017 Q4 | 88.43 Million USD | 10.0% |
| 2017 FY | 302.23 Million USD | 40.57% |
| 2017 Q3 | 80.39 Million USD | 6.03% |
| 2017 Q2 | 75.82 Million USD | 31.7% |
| 2017 Q1 | 57.57 Million USD | -7.69% |
| 2016 FY | 215 Million USD | 48.87% |
| 2016 Q2 | 50.42 Million USD | 17.05% |
| 2016 Q4 | 62.37 Million USD | 9.79% |
| 2016 Q3 | 56.81 Million USD | 12.67% |
| 2016 Q1 | 43.07 Million USD | 0.98% |
| 2015 Q4 | 42.65 Million USD | 10.55% |
| 2015 FY | 144.42 Million USD | 18.34% |
| 2015 Q3 | 38.58 Million USD | 10.08% |
| 2015 Q2 | 35.05 Million USD | 24.59% |
| 2015 Q1 | 28.13 Million USD | -8.66% |
| 2014 Q2 | 29.67 Million USD | 226.78% |
| 2014 Q1 | 9.08 Million USD | -12.13% |
| 2014 Q4 | 30.8 Million USD | -41.32% |
| 2014 FY | 122.04 Million USD | 915.43% |
| 2014 Q3 | 52.48 Million USD | 76.88% |
| 2013 FY | 12.01 Million USD | 712.09% |
| 2013 Q4 | 10.33 Million USD | 722.12% |
| 2013 Q3 | 1.25 Million USD | 347.33% |
| 2013 Q2 | 281 Thousand USD | 91.16% |
| 2013 Q1 | 147 Thousand USD | -86.51% |
| 2012 Q2 | 91 Thousand USD | -56.25% |
| 2012 Q1 | 208 Thousand USD | 102.11% |
| 2012 Q3 | 91 Thousand USD | 0.0% |
| 2012 Q4 | 1.09 Million USD | 1097.8% |
| 2012 FY | 1.48 Million USD | 84.31% |
| 2011 Q3 | 11 Thousand USD | -98.53% |
| 2011 Q4 | -9.84 Million USD | -89600.0% |
| 2011 Q1 | - USD | 100.0% |
| 2011 FY | 803 Thousand USD | 657.55% |
| 2011 Q2 | 750 Thousand USD | 0.0% |
| 2010 Q4 | -8.62 Million USD | 0.0% |
| 2010 FY | 106 Thousand USD | -99.72% |
| 2009 FY | 37.92 Million USD | 326.65% |
| 2009 Q4 | -5.13 Million USD | 0.0% |
| 2008 FY | 8.88 Million USD | 109.97% |
| 2007 FY | 4.23 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Theratechnologies Inc. | 81.76 Million USD | -643.018% |
| Harrow Health, Inc. | 130.19 Million USD | -366.631% |
| Dynavax Technologies Corporation | 232.28 Million USD | -161.542% |
| Biofrontera Inc. | 34.07 Million USD | -1683.103% |
| Cronos Group Inc. | 88.84 Million USD | -583.83% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -4670.483% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | -37.22% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -9227.574% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -1435.986% |
| Radius Health, Inc. | 2.88 Billion USD | 78.922% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -1780.361% |
| DURECT Corporation | 8.54 Million USD | -7007.171% |
| ProPhase Labs, Inc. | 44.38 Million USD | -1268.784% |
| Safety Shot Inc | 202.67 Thousand USD | -299658.721% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 40.303% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -31402.305% |
| Alvotech | 91.43 Million USD | -564.437% |
| Assertio Holdings, Inc. | 152.06 Million USD | -299.504% |
| Rockwell Medical, Inc. | 83.61 Million USD | -626.595% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -2421.589% |
| Procaps Group S.A. | 409.92 Million USD | -48.205% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | -30.827% |
| SCYNEXIS, Inc. | 140.14 Million USD | -333.507% |
| Aytu BioPharma, Inc. | 81 Million USD | -650.007% |
| Viatris Inc. | 15.42 Billion USD | 96.062% |
| OptiNose, Inc. | 70.98 Million USD | -755.82% |
| SIGA Technologies, Inc. | 139.91 Million USD | -334.2% |
| Tilray Brands, Inc. | 788.94 Million USD | 22.995% |
| PetIQ, Inc. | 1.1 Billion USD | 44.869% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -2421.589% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 67.807% |
| Guardion Health Sciences, Inc. | 12.24 Million USD | -4859.942% |
| Alimera Sciences, Inc. | 80.75 Million USD | -652.311% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | -7.191% |
| Silver Spike Investment Corp. | 11.72 Million USD | -5082.683% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Organogenesis Holdings Inc. | 433.14 Million USD | -40.26% |
| Journey Medical Corporation | 79.18 Million USD | -667.256% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -10334.224% |
| Alpha Teknova, Inc. | 36.68 Million USD | -1556.093% |
| Clever Leaves Holdings Inc. | 17.41 Million USD | -3388.092% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -373.66% |
| PainReform Ltd. | - USD | -Infinity% |
| Cosmos Health Inc. | 53.37 Million USD | -1038.173% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -2072.589% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -46560.599% |
| Embecta Corp. | 1.12 Billion USD | 45.796% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Talphera, Inc. | 651 Thousand USD | -93221.198% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 9.994% |
| Incannex Healthcare Limited | 12 Thousand USD | -5062575.0% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -56339.816% |
| Shineco, Inc. | 9.8 Million USD | -6098.02% |
| Procaps Group, S.A. | 409.92 Million USD | -48.205% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | -24.795% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -1101.038% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 53.139% |
| Alvotech | 91.43 Million USD | -564.437% |
| Hempacco Co., Inc. | 4.04 Million USD | -14916.696% |
| Eagle Pharmaceuticals, Inc. | 316.61 Million USD | -91.883% |
| Bright Green Corporation | 401.49 Thousand USD | -151216.219% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -422.221% |
| Kamada Ltd. | 144.75 Million USD | -319.678% |
| Indivior PLC | 1.09 Billion USD | 44.417% |
| Evoke Pharma, Inc. | 5.18 Million USD | -11626.778% |
| Flora Growth Corp. | 76.07 Million USD | -698.624% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -56339.816% |
| Evolus, Inc. | 202.08 Million USD | -200.626% |
| HUTCHMED (China) Limited | 837.99 Million USD | 27.503% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 5.722% |
| Akanda Corp. | 2.16 Million USD | -28025.295% |